BD Reports Fourth Quarter and Full Year Fiscal 2022 Financial Results

Execution of BD 2025 Strategy Driving Consistent Durable Growth Q4 revenue from continuing operations of $4.8 billion decreased 1.8% as reported and increased...

Related Keywords

China ,United States ,Russia ,Ukraine ,Tom Polen ,Francesca Demartino ,Troy Kirkpatrick ,Business Revenues ,Embecta Corp ,Linkedin ,Medication Delivery Solutions ,Bd Life Sciences Revenues ,Solutions Revenues ,Bd Life Sciences ,Revenue Growth ,Research Cloud ,Exchange Commission ,Life Sciences Segment ,Business Revenue Growth ,Medication Management Solutions ,European Union Medical Device Regulation ,Driving Consistent Durable ,Continuing Operations ,Diabetes Care ,Quarter Fiscal ,Months Ended September ,Diluted Earnings ,Organic Revenue Growth ,Pharmaceutical Systems ,Pharmacy Automation ,Connected Medication Management ,Integrated Diagnostic Solutions ,Peripheral Intervention ,Critical Care ,Advanced Repair ,Full Year Fiscal ,Devices Regulations ,Investor Relations ,Public Relations ,Delivery Solutions ,Diagnostic Testing ,Base Organic Revenue Growth ,Medical Segment ,Business Revenue ,Only Diagnostic Testing ,Foreign Currency ,Bd Becton ,Ickinson And Company ,